Viewing Study NCT05585632

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:40 PM
Ignite Modification Date: 2026-01-05 @ 6:59 AM
Study NCT ID: NCT05585632
Status: COMPLETED
Last Update Posted: 2024-03-08
First Post: 2022-10-14
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
Sponsor: ModernaTX, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None SARS-CoV-2 View
None Influenza View
None RSV View
Keywords:

Keywords

Keyword Brief Keyword Text View
None mRNA-1230 Vaccine View
None mRNA-1045 Vaccine View
None SARS-CoV-2 Vaccine View
None Influenza Vaccine View
None RSV Vaccine View
None Coronavirus View
None Virus Diseases View
None Messenger RNA View
None COVID-19 View
None COVID-19 Vaccine View
None Moderna View